

12. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. *Proc Natl Acad Sci USA*. 2013;110:E2987–E2996.
13. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. *Nat Rev Cancer*. 2012;12:89–103.
14. Spiegel DR, Edelman MJ, O'Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. *J Clin Oncol*. 2017;35:412–420.
15. Patra M, Eichenberger LS, Fischer G, Holland JP. Photochemical conjugation and one-pot radiolabelling of antibodies for immuno-PET. *Angew Chem Int Ed Engl*. 2019;58:1928–1933.
16. Eichenberger LS, Patra M, Holland JP. Photoactive chelates for radiolabelling proteins. *Chem Commun (Camb)*. 2019;55:2257–2260.
17. Patra M, Klingler S, Eichenberger LS, Holland J. Simultaneous photoradiochemical labelling of antibodies for immuno-PET. *iScience*. 2019;13:416–431.
18. Fay R, Gut M, Holland JP. Photoradiosynthesis of ⁶⁸Ga-labeled HBED-CC-azepin-MetMab for immuno-PET of c-MET receptors. *Bioconjug Chem*. 2019;30:1814–1820.
19. Gut M, Holland JP. Synthesis and photochemical studies on gallium and indium complexes of DTPA-PEG3-ArN3 for radiolabelling antibodies. *Inorg Chem*. 2019;58:12302–12310.
20. Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. *J Nucl Med*. 2008;49:1114–1131.
21. Perk LR, Vosjan MJWD, Visser GWM, et al. P-isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. *Eur J Nucl Med Mol Imaging*. 2010;37:250–259.
22. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson S, Lewis JS. ⁸⁹Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. *J Nucl Med*. 2010;51.
23. *Guide for the Care and Use of Laboratory Animals*. 8th ed. Washington, DC: Institute for Laboratory Animal Research; 2011.
24. Xiang H, Bender BC, Reyes AE, et al. Onartuzumab (MetMab): using nonclinical pharmacokinetic and concentration-effect data to support clinical development. *Clin Cancer Res*. 2013;19:5068–5078.
25. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. *J Immunol Methods*. 1984;72:77–89.
26. Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD. Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection. *Nat Protoc*. 2012;7:1138–1144.
27. Mattes MJ. Limitations of the Lindmo method in determining immunoreactivity. *Int J Cancer*. 1995;61:286–288.
28. Junghans RP. Cruel antibody fictions! Cellular antigen enumeration by “saturation” binding. *Immunol Today*. 1999;20:401–406.
29. Konishi S, Hamacher K, Vallabhajosula S, et al. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? *Cancer Biother Radiopharm*. 2004;19:706–715.
30. Gritsan NP, Platz MS. Kinetics, spectroscopy, and computational chemistry of arylnitrenes. *Chem Rev*. 2006;106:3844–3867.
31. Gritsan N, Platz M. Photochemistry of azides: the azide/nitrene interface. In: Bräse S, Banert K, eds. *Organic Azides: Syntheses and Applications*. Hoboken, NJ: Wiley; 2010:311–364.
32. Borden WT, Gritsan NP, Hadad CM, Karney WL, Kemnitz CR, Platz MS. The interplay of theory and experiment in the study of phenylnitrene. *Acc Chem Res*. 2000;33:765–771.
33. Platz MS. Comparison of Phenylcarbene and Phenylnitrene. *Acc Chem Res*. 1995;28:487–492.
34. Holland JP. Chemical Kinetics of Radiolabelling Reactions. *Chemistry*. 2018;24:16472–16483.
35. Richardson-Sanchez T, Tieu W, Gotsbacher MP, Telfer TJ, Codd R. Exploiting the biosynthetic machinery of: *Streptomyces pilosus* to engineer a water-soluble zirconium(IV) chelator. *Org Biomol Chem*. 2017;15:5719–5730.

Erratum

In the article “Novel ‘Add-On’ Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents,” by Chen et al. (*J Nucl Med*. 2017;58:590–597), Figure 1, which displays the chemical structure of NMEB-RGD, has chiral centers incorrectly drawn. The corrected figure appears below. The authors regret the error.




FIGURE 1.